emactuzumab
mAbexperimental
Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against colony stimulating factor 1 receptor (CSF-1R) expressed on macrophages and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT). — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01494688)
Timeline
Indications
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEmactuzumab ↗
- ChEMBLCHEMBL3545370 ↗
- ChEMBLCHEMBL2109324 ↗
Also known as
- emactuzumab
- emactuzumab
- emactuzumab
- rg7155
- rg-7155
- ro5509554
- ro-5509554
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05417789 | Phase 3 | Jul 18, 2022 | SynOx Therapeutics Ltd |
| NCT03369964 | Phase 1 | Mar 14, 2018 | Roche |
| NCT03193190 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2017 | Roche |
| NCT02923739 | Phase 2 | May 5, 2017 | Genentech, University of Texas at Houston |
| NCT02760797 | Phase 1 | May 1, 2016 | Roche |
| NCT02323191 | Phase 1 | Jan 19, 2015 | Roche |
| NCT01494688 | Phase 1 | Dec 1, 2011 | Roche |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 2 | 2011 |
| Genentech | For profit | 1 | 0 | 1 | 2017 |
| SynOx Therapeutics Ltd | For profit | 1 | 1 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2017 |
4 organizations
Page 1 / 1